These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35769483)

  • 21. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer.
    Gong Z; Zhang J; Guo W
    Cancer Med; 2020 Dec; 9(23):9052-9063. PubMed ID: 33030278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblastic galectin-1-fostered invasion and metastasis are mediated by TGF-β1-induced epithelial-mesenchymal transition in gastric cancer.
    You X; Wu J; Zhao X; Jiang X; Tao W; Chen Z; Huang C; Zheng T; Shen X
    Aging (Albany NY); 2021 Jul; 13(14):18464-18481. PubMed ID: 34260413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weighted Gene Co-expression Network Analysis Identifies a Cancer-Associated Fibroblast Signature for Predicting Prognosis and Therapeutic Responses in Gastric Cancer.
    Zheng H; Liu H; Li H; Dou W; Wang X
    Front Mol Biosci; 2021; 8():744677. PubMed ID: 34692770
    [No Abstract]   [Full Text] [Related]  

  • 25. A prognostic marker LTBP1 is associated with epithelial mesenchymal transition and can promote the progression of gastric cancer.
    Jiang X; Yin S; Yin X; Wang Y; Fang T; Yang S; Bian X; Li G; Xue Y; Zhang L
    Funct Integr Genomics; 2024 Feb; 24(1):30. PubMed ID: 38358412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
    Hu B; Meng Y; Qu C; Wang BY; Xiu DR
    Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic marker elastin correlates with epithelial-mesenchymal transition and vimentin-positive fibroblasts in gastric cancer.
    Fang T; Zhang L; Yin X; Wang Y; Zhang X; Bian X; Jiang X; Yang S; Xue Y
    J Pathol Clin Res; 2023 Jan; 9(1):56-72. PubMed ID: 36226731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE.
    Furukawa K; Hatakeyama K; Terashima M; Nagashima T; Urakami K; Ohshima K; Notsu A; Sugino T; Yagi T; Fujiya K; Kamiya S; Hikage M; Tanizawa Y; Bando E; Kanai Y; Akiyama Y; Yamaguchi K
    Gastric Cancer; 2022 Jan; 25(1):138-148. PubMed ID: 34476642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new risk model based on a 11-m
    Lei L; Li N; Yuan P; Liu D
    BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
    Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
    Front Immunol; 2021; 12():651033. PubMed ID: 34054812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galectin-1 from cancer-associated fibroblasts induces epithelial-mesenchymal transition through β1 integrin-mediated upregulation of Gli1 in gastric cancer.
    Chong Y; Tang D; Xiong Q; Jiang X; Xu C; Huang Y; Wang J; Zhou H; Shi Y; Wu X; Wang D
    J Exp Clin Cancer Res; 2016 Nov; 35(1):175. PubMed ID: 27836001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Ferroptosis-Related Gene Risk Signature for Predicting Prognosis and Immunotherapy Response in Gastric Cancer.
    Liu SJ; Yang YB; Zhou JX; Lin YJ; Pan YL; Pan JH
    Dis Markers; 2021; 2021():2385406. PubMed ID: 34868391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COL8A1 Predicts the Clinical Prognosis of Gastric Cancer and Is Related to Epithelial-Mesenchymal Transition.
    She Y; Zhao X; Wu P; Xue L; Wan S; Zhang L; Li C; Cai H; Li Y
    Biomed Res Int; 2022; 2022():7567447. PubMed ID: 35774273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer.
    Song W; Bai Y; Zhu J; Zeng F; Yang C; Hu B; Sun M; Li C; Peng S; Chen M; Sun X
    World J Surg Oncol; 2021 Jul; 19(1):216. PubMed ID: 34281542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition.
    Fan Y; Wang YF; Su HF; Fang N; Zou C; Li WF; Fei ZH
    J Hematol Oncol; 2016 Jul; 9(1):57. PubMed ID: 27439973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
    Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
    Front Immunol; 2021; 12():805883. PubMed ID: 35095892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel adenosine signalling-based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response.
    Yu Y; Wang Y; Xi D; Wang N; Gao L; Shi Q; Yu R; Li H; Xiang L; Maswikiti EP; Chen H
    Cell Biol Int; 2023 Sep; 47(9):1650-1664. PubMed ID: 37366248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer.
    Yang S; Li G; Yin X; Wang Y; Jiang X; Bian X; Fang T; Yin S; Zhang L; Xue Y
    J Pathol Clin Res; 2023 Sep; 9(5):391-408. PubMed ID: 37395335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
    Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
    Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.